Lichen Planus Market Report 2026

Lichen Planus Market Overview

• Lichen Planus market size has reached to $1.26 billion in 2025 • Expected to grow to $1.76 billion in 2030 at a compound annual growth rate (CAGR) of 6.8% • Growth Driver: Increasing Prevalence Of Autoimmune Diseases Fueling The Growth Of The Market Due To Its Association With Immune System Dysregulation • Market Trend: Innovative Solutions In Liposomal Formulations Fuel The Market Growth Due To Enhanced Targeted Drug Delivery And Reduced Systemic Side Effects • North America was the largest region in 2025.

What Is Covered Under Lichen Planus Market?

Lichen planus is a chronic inflammatory condition that affects the skin, mucous membranes, and sometimes the nails or hair. It is characterized by the development of purplish, itchy, flat-topped bumps or lesions, most commonly on the wrists, ankles, and lower back. It can also affect the inside of the mouth, causing white, lace-like patches or painful sores. The main disease types of lichen planus are lichen planus, oral lichen planus, genital lichen planus, and lichen planus pigmentosus. Lichen planus is a long-term inflammatory condition where the immune system mistakenly attacks the skin and mucous membranes. The various treatment types comprise topical therapies, systemic therapies, phototherapy, and alternative treatments. The different routes of administration include topical, oral, intravenous, and intradermal and cater to end users such as hospitals, homecare, specialty clinics, and others.

What Is The Lichen Planus Market Growth Forecast?

The lichen planus market size is expected to see strong growth in the next few years. It will grow to $1.76 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to growing demand for advanced immunotherapies, rising focus on long-term symptom control, expansion of biologic treatment research, increasing integration of digital dermatology tools, advancements in targeted anti-inflammatory drugs. Major trends in the forecast period include increasing adoption of targeted immunomodulatory therapies, rising use of topical and systemic treatment combinations, increasing focus on chronic disease management, expansion of personalized dermatology care, improved patient education and disease monitoring.

Global Lichen Planus Market Segmentation

1) By Disease Type: Lichen Planus, Oral Lichen Planus, Genital Lichen Planus, Lichen Planus Pigmentosus 2) By Treatment Type: Topical Therapies, Systemic Therapies, Phototherapy 3) By Route Of Administration: Topical, Oral, Intravenous 4) By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users Subsegments: 1) By Lichen Planus: Papular Lichen Planus, Hypertrophic Lichen Planus, Actinic Lichen Planus, Linear Lichen Planus, Annular Lichen Planus 2) By Oral Lichen Planus: Reticular Oral Lichen Planus, Erosive Oral Lichen Planus, Atrophic Oral Lichen Planus, Plaque-Like Oral Lichen Planus, Bullous Oral Lichen Planus 3) By Genital Lichen Planus: Erosive Genital Lichen Planus, Papular Genital Lichen Planus, Annular Genital Lichen Planus, Vulvovaginal-Gingival Syndrome 4) By Lichen Planus Pigmentosus: Diffuse Lichen Planus Pigmentosus, Blotchy Lichen Planus Pigmentosus, Linear Lichen Planus Pigmentosus, Perifollicular Lichen Planus Pigmentosus, Flexural Lichen Planus Pigmentosus

What Is The Driver Of The Lichen Planus Market?

The increasing prevalence of autoimmune diseases is expected to propel the growth of the lichen planus market going forward. Autoimmune diseases are conditions where the immune system mistakenly attacks the body's own healthy cells. It includes rheumatoid arthritis, lupus, type 1 diabetes, multiple sclerosis, and psoriasis. The prevalence of autoimmune diseases is increasing due to genetic predisposition, as specific gene variations influence immune system activity and connective tissue abnormalities. The rising incidence of autoimmune diseases not only reflects a broader dysfunction in immune regulation but also contributes to an increased number of lichen planus cases. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, approximately 514,000 (2.0%) people were living with rheumatoid arthritis in 2022, contributing to 2.0% of the total disease burden and 16% of the musculoskeletal conditions burden in 2023, with 1,322 deaths (5.1 deaths per 100,000 population) recorded in 2022, accounting for 0.7% of all deaths. Therefore, the increasing prevalence of autoimmune diseases is driving the growth of the lichen planus industry.

Key Players In The Global Lichen Planus Market

Major companies operating in the lichen planus market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc, AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Dr. Reddy's Laboratories Ltd, Amneal Pharmaceuticals Inc., Hikma Pharmaceuticals plc, LEO Pharma A/S, Basilea Pharmaceutica Ltd., UCB S.A., Almirall SA, Lipella Pharmaceuticals Inc.

Global Lichen Planus Market Trends and Insights

Major companies operating in the lichen planus market are focusing on developing innovative solutions such as liposomal formulations to enhance targeted drug delivery and reduce systemic side effects. Liposomal formulations are drug delivery systems where active ingredients are encapsulated within liposomes, tiny spherical vesicles made of lipid bilayers that improve drug stability, enhance absorption, and allow for targeted delivery with reduced systemic side effects. For instance, in February 2025, Lipella Pharmaceuticals Inc., a US-based biotechnology company that specializes in developing treatments for serious diseases, received US Food and Drug Administration approval for an expanded access program (EAP) for LP-310. It is a liposomal formulation of tacrolimus designed to provide targeted relief for oral lichen planus (OLP) patients while minimizing systemic exposure. This program allows patients with serious or life-threatening conditions, who have unmet medical needs, to access treatments outside of clinical trials before they are officially approved.

What Are Latest Mergers And Acquisitions In The Lichen Planus Market?

In September 2024, Eli Lilly and Company, a US-based pharmaceutical company, partnered with EVA Pharma to enhance access to baricitinib (Olumiant) in 49 low- to middle-income countries across Africa. This partnership aims to reach an estimated 20,000 patients by 2030, addressing conditions such as lichen planus, rheumatoid arthritis, alopecia areata, and atopic dermatitis. As part of the agreement, Lilly will share specific manufacturing know-how to empower EVA Pharma to locally produce and distribute the medication. EVA Pharma is an Egypt-based pharmaceutical company specializing in the production and marketing of generic prescription formulations and drugs across various therapeutic areas.

Regional Outlook

North America was the largest region in the lichen planus market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Lichen Planus Market?

The lichen planus market consists of revenues earned by entities by providing services such as narrowband UVB therapy, oral hygiene counseling, and dental check-ups. The market value includes the value of related goods sold by the service provider or included within the service offering. The lichen planus market also includes sales of topical corticosteroids, systemic immunosuppressants, antihistamines, biologic therapies, phototherapy equipment, diagnostic tools, and herbal and alternative remedies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.